The relationship between atherosclerosis, cognitive impairment, and depression in old age;De relatie tussen atherosclerose, cognitieve achteruitgang en depressie bij ouderen

Nederlands Tijdschrift voor Geneeskunde

Volumn 150, Issue 42, 2006, Pages 2307-2311

  Vinkers, D J ^a,b   Van Der Mast, R C ^a   Stek, M L ^c,d   Westendorp, R G J ^a   Gussekloo, J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rivierduinen   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d GGZ Foundation for Mental Health Care Buitenamstel   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ALZHEIMER DISEASE; APATHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; HEART INFARCTION; HUMAN; MINI MENTAL STATE EXAMINATION; REVIEW; RISK FACTOR; SENESCENCE;

AGED; AGED, 80 AND OVER; AGING; ATHEROSCLEROSIS; COGNITION DISORDERS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DEPRESSION; HUMANS; NETHERLANDS; RISK FACTORS;

EID: 33750470350     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Skoog I, Nilsson L, Palmertz B, Andreasson LA, Svanborg A. A population-based study of dementia in 85-year-olds. N Engl J Med. 1993; 328:153-8.
2. Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry. 1999;174:307-11.
3. Charney DS, Reynolds 3rd CF, Lewis L, Lebowitz BD, Sunderland T, Alexopoulos GS, et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry. 2003;60:604-72.
4. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475-83.
5. Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003;160:857-66.
6. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. Lancet Neurol. 2003;2:89-98.
7. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M. 'Vascular depression' hypothesis. Arch Gen Psychiatry. 1997;54:915-22.
8. Gussekloo J, Craen AJM de, Exel E van, Bootsma-van der Wiel A, Westendorp RGJ. Oorzaken en gevolgen van cognitieve achteruitgang op hoge leeftijd; de 'Leiden 85-plus Studie'. Ned Tijdschr Geneeskd. 2004;148:979-83.
9. De la Torre JC. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol. 2004;3: 184-90.
10. Neuropathology Group. Medical Research Council Cognitive Function and Ageing Study. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet. 2001;357:169-75.
11. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652-9.
12. O'Brien JT, Ames D, Schweitzer I. White matter changes in depression and Alzheimer's disease: a review of magnetic resonance imaging studies. Int J Geriatr Psychiatry. 1996;11:681-94.
13. Vermeer SE, Prins ND, Heijer T den, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215-22.
14. Breteler MMB, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ. 1994;308:1604-8.
15. Breteler MMB. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging. 2000;21:153-60.
16. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352:1347-51.
17. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 2000;54:240-2.
18. Collins R, Armitage J, Parish S Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Heart Protection Study Collaborative Group. Lancet. 2004;363:757-67.
19. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278: 1349-56.
20. Kalmijn S, Feskens EJM, Launer LJ, Kromhout D. Cerebrovascular disease, the apolipoprotein e4 allele, and cognitive decline in a community-based study of elderly men. Stroke. 1996;27:2230-5.
21. Exel E van, Gussekloo J, Houx P, Craen AJM de, Macfarlane PW, Bootsma-van der Wiel A, et al. Atherosclerosis and cognitive impairment are linked in the elderly. The Leiden 85-plus Study. Atherosclerosis. 2002;165:353-9.
22. Vinkers DJ, Stek ML, Mast RC van der, Craen AJM de, le Cessie S, Jolles J, et al. Generalized atherosclerosis, cognitive decline, and depressive symptoms in old age. Neurology. 2005;65:107-12.
23. Heun R, Kockler M, Papassotiropoulos A. Distinction of early- and late-onset depression in the elderly by their lifetime symptomatology. Int J Geriatr Psychiatry. 2000;15:1138-42.
24. Alexopoulos GS. Does vascular disease cause late-life depression? Econom Neurosci. 2001;3:49-56.
25. Aben I, Verhey F, Strik J, Lousberg R, Lodder J, Honig A. A comparative study into the one year cumulative incidence of depression after stroke and myocardial infarction. J Neurol Neurosurg Psychiatry. 2003;74:581-5.
26. Prince MJ, Harwood RH, Thomas A, Mann AH. A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression. The Gospel Oak Project VII. Psychol Med. 1998;28:337-50.
27. Henderson AS, Korten AE, Jacomb PA, Mackinnon AJ, Jorm AF, Christensen H, et al. The course of depression in the elderly: a longitudinal community-based study in Australia. Psychol Med. 1997;27:119-29.
28. Steffens DC, McQuoid DR, Krishnan KRR. Cholesterol-lowering medication and relapse of depression. Psychopharmacol Bull. 2003;37:92-8.
29. Cervilla J, Prince M, Rabe-Hesketh S. Vascular disease risk factors as determinants of incident depressive symptoms: a prospective community-based study. Psychol Med. 2004;34:635-41.
30. Kim JM, Stewart R, Shin IS, Yoon JS. Vascular disease/risk and late-life depression in a Korean community population. Br J Psychiatry. 2004;185:102-7.
31. Groot JC de, Leeuw FE de, Oudkerk M, Hofman A, Jolles J, Breteler MMB. Cerebral white matter lesions and depressive symptoms in elderly adults. Arch Gen Psychiatry. 2000;57:1071-6.
32. Versluis CE, Mast RC van der, Buchem MA van, Bollen ELEM, Blauw GJ, Eekhof JAH, et al. Progression of cerebral white matter lesions is not associated with development of depressive symptoms in elderly subjects at risk of cardiovascular disease: the PROSPER Study. Int J Geriatr Psychiatry. 2006;21:375-81.
33. Steffens DC, Krishnan KRR, Crump C, Burke GL. Cerebrovascular disease and evolution of depressive symptoms in the Cardiovascular Health Study. Stroke. 2002;33:1636-44.
34. Sitoh YY, Sitoh YY, Sahadevan S. Clinical significance of cerebral white matter lesions in older Asians with suspected dementia. Age Ageing. 2004;33:67-71.
35. Thomas AJ, Perry R, Kalaria RN, Oakley A, McMeekin W, O'Brien JT. Neuropathological evidence for ischemia in the white matter of the dorsolateral prefrontal cortex in late-life depression. Int J Geriatr Psychiatry. 2003;18:7-13.
36. Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann N Y Acad Sci. 1995;769:1-13.
37. Fones CSL. Distinguishing apathy syndromes from vascular depression. Arch Gen Psychiatry. 1998;55:844-5.
38. Thomas AJ, Perry R, Barber R, Kalaria RN, O'Brien JT. Pathologies and pathological mechanisms for white matter hyperintensities in depression. Ann N Y Acad Sci. 2002;977:333-9.
39. Schmand B, Hooijer C, Jonker C, Lindeboom J, Havekes LM. Apolipoprotein E phenotype is not related to late-life depression in a population-based sample. Soc Psychiatry Psychiatr Epidemiol. 1998; 33:21-6.
40. Wilson RS, Mendes de Leon CF, Bennett DA, Bienias JL, Evans DA. Depressive symptoms and cognitive decline in a community population of older persons: a community-based prospective study. J Neurol Neurosurg Psychiatry. 2004;75:126-9.
41. Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry. 1999;56:261-6.
42. Nebes RD, Pollock BG, Houck PR, Butters MA, Mulsant BH, Zmuda MD, et al. Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine. J Psychiatr Res. 2000; 37:99-108.
43. Bennett DA, Wilson RS, Schneider JA, Bienias JL, Arnold SE. Cerebral infarctions and the relationship of depression symptoms to level of cognitive functioning in older persons. Am J Geriatr Psychiatry. 2004;12:211-9.
44. Vinkers DJ, Gussekloo J, Stek ML, Westendorp RGJ, Mast RC van der. Temporal relation between depression and cognitive impairment in old age: prospective population based study. BMJ. 2004;329:881.